Stockscreener 앱 받기
9.18
4.87%
-0.47
Atara Biotherapeutics Inc 주식(ATRA)의 최신 뉴스
Atara Biotherapeutics Share PriceATRA, RNS News, Articles, Quotes, & Charts (NASDAQ:ATRA) - Proactive financial news
Atara Biotherapeutics Inc (ATRA) Stock Price, Trades & News - GuruFocus
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily
Atara, Pierre Fabre take third shot at FDA approval of Ebvallo - BioWorld News
Atara Partner Resubmits Tabelecleucel FDA Application - grafa.com
Atara Biotherapeutics (ATRA) Sees FDA Resubmission for Tabelecle - GuruFocus
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration - Business Wire
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - accessnewswire.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Independent Director of Atara Biotherapeutics Picks Up 272% More Stock - simplywall.st
New Form 4 - Moomoo
Atara Biotherapeutics (ATRA) Director Brian Cherry Buys 104,166 Shares - GuruFocus
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com Canada
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com Australia
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com Nigeria
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - Investing.com India
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares - investing.com
Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares By Investing.com - Investing.com South Africa
Atara Biotherapeutics Director Purchased Shares Worth Over $999K - TradingView
(ATRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics president and CEO sells $40,882 in shares By Investing.com - Investing.com Nigeria
Atara Biotherapeutics president and CEO sells $40,882 in shares - Investing.com India
Atara Biotherapeutics (ATRA) employee plans 5,062-share tax sale - Stock Titan
Atara Biotherapeutics president and CEO sells $40,882 in shares - Investing.com
Atara (ATRA) Results Breakdown: Profit Per Share Surpasses Its Benchmark on the Day; Post-Report Move: The Stock Records a 1.26% Increase at the CloseProfit Growth Outlook - vinanet.vn
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Why (ATRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Atara Biotherapeutics (ATRA): Point72 entities report 7.6% beneficial stake - Stock Titan
Atara Biotherapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ATRA | US0465132068 - marketscreener.com
Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com Nigeria
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics cuts costs 87%, extends cash runway to mid-2027 - scanx.trade
Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com
Is Atara Biotherapeutics Inc (ATRA) Positioned for Growth After - GuruFocus
Atara Biotherapeutics (NASDAQ:ATRA) Announces Quarterly Earnings Results - MarketBeat
Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates - Investing.com
Atara Biotherapeutics 2Q 2026: Revenue $0.63M, Net loss $(9.0)M — 10-Q Summary - TradingView
Atara Biotherapeutics: Q2 Earnings Snapshot - AOL.com
BRIEF-Atara Biotherapeutics Q2 EPS USD -0.32 - TradingView
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress - Business Wire
Atara Biotherapeutics (ATRA) Rallies 3.8% to $8.94, Approaching Resistance at $9.39Negative Gamma - vinanet.vn
Atara Biotherapeutics (NASDAQ:ATRA): What Could Today’s Update Reveal About Program Focus And Funding Discipline? - Kalkine Media
4.22%
자본화:
|
볼륨(24시간):